AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03781154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exercise
Description: Patients will exercise in a virtual group for 60 minutes, twice a week. Five social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
Study NCT06227416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: punch biopsy (2-4 mm) depending on the size of the AK lesion.
Study NCT03303625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF (1*10^11 vp)
Description: Participants will receive two doses of 0.5 milliliter (mL) (1\*10\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
Study NCT03303625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF (5*10^10 vp)
Description: RSV seropositive participants will receive two doses of 0.25 mL (5\*10\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
Study NCT03303625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
Study NCT02263742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer whole health intervention
Description: Provide wraparound peer support, education, and navigation to individuals
Study NCT02263742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EBPs at Wellness Center
Description: four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
Study NCT00273806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for 4 behavioral risks by medical assistants.
Study NCT01169415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: Participants will receive a protracted (30 days) course of dexamethasone after surgery.
Study NCT01169415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive a protracted (14 days) course of dexamethasone after surgery.
Study NCT00882596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
Study NCT01926418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning tasks
Description: Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning.
Study NCT03868618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genio™ system
Description: The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
Study NCT04542824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epcoritamab (monotherapy)
Description: Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
Study NCT04542824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epcoritamab
Description: Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
Study NCT00296478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin
Description: Endometrin 100mg TID x 10weeks
Study NCT03274076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Oral medication tofacitinib 5 mg twice a day for 24 weeks.
Study NCT00296478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone
Description: Crinone QD x 10weeks
Study NCT03274076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral Placebo 5 mg twice a day for 24 weeks
Study NCT03879538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
Study NCT03879538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
Study NCT02553889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ISIS 416858
Description: subcutaneous injection
Study NCT02553889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 416858
Description: subcutaneous injection
Study NCT02553889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study NCT05208034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
Study NCT01530334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg
Description: Gefitinib 250mg once daily
Study NCT04542824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Description: 21-day cycles
Study NCT01753167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCMV3068A
Description: Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Study NCT01753167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCMV5322A
Description: Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Study NCT01753167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Study NCT04191850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Port Video-Assisted Thoracoscopic Surgery
Description: Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
Study NCT04191850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Port Video-Assisted Thoracoscopic Surgery
Description: Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
Study NCT00950365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT00950365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02909920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
Study NCT02909920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy
Description: Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
Study NCT01774838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 3 months treatment
Study NCT01774838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 3 months treatment
Study NCT02839590 — intervention group
Intervention type: DEVICE
Intervention: HiFU
Description: Ciliary Ablation Treatment ( HiFu ultrasound treatment)
Study NCT02839590 — intervention group
Intervention type: DEVICE
Intervention: Baerveldt implant
Description: External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
Study NCT02839590 — intervention group
Intervention type: DEVICE
Intervention: Ahmed implant
Description: External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
Study NCT02839590 — intervention group
Intervention type: DEVICE
Intervention: STARflo
Description: Suprachoroidal Shunt Surgery (STARflo)
Study NCT02839590 — intervention group
Intervention type: DEVICE
Intervention: Hydrus Microstent implant
Description: Trans-trabecular meshwork implants (Hydrus Microstent implant).
Study NCT02839590 — intervention group
Intervention type: DEVICE
Intervention: iStent implant
Description: Trans-trabecular meshwork implants (iStent implant).
Study NCT02839590 — intervention group
Intervention type: DEVICE
Intervention: Kahook Dual Blade
Description: It removes part of the trabecular meshwork
Study NCT01636401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aclidinium bromide 400 μg
Study NCT01636401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aclidinium bromide placebo
Study NCT03703765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lower limb volume estimation
Description: The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort.
Study NCT02730455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm
Study NCT02730455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study NCT03306680 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will be assigned to treatment doses using the TITE-CRM model.
Study NCT03235076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
Study NCT00840294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Study NCT04464915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol swab
Description: Treatment will be administered by taking one deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes or every 20 minutes for a total of one hour.
Study NCT00950365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02668133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: the nutritional supplement to be used in this trial is a SQ-LNS
Description: Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
Study NCT02668133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lipid-based nutrient supplement (SQ-LNS) with phytase
Description: • Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS) added during manufacturing
Study NCT02668133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc
Description: delivered orally in sugar solution
Study NCT02668133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc
Description: delivered orally in sugar solution
Study NCT02668133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg isotopically enriched 68Zn
Description: administered intravenously
Study NCT02668133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 mg isotopically enriched 68Zn
Description: administered intravenously
Study NCT02645214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-antiseptic scrubs
Study NCT02645214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiseptic scrubs
Study NCT01512082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field devices
Description: Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
Study NCT04081051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)
Description: Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
Study NCT01220596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and Pegylated interferon α-2a Sequential Treatment Group
Description: Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
Study NCT01220596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon α-2a Monotreatment Group
Description: Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
Study NCT00950365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT01512082 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsed electromagnetic field devices
Description: Every persons received two sham pulsed electromagnetic field devices.
Study NCT03235154 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sofosbuvir/velpatasvir
Description: 12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
Study NCT01922089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 50 mg/100 mg/200 mg bid
Study NCT00645073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: Two 300 mg cefdinir capsules on Study Days 1-10.
Study NCT00645073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: Two 250 mg levofloxacin capsules on Study Days 1-10
Study NCT00950365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT00229970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: 7 mg or 14 mg single injection
Study NCT04542824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and oxaliplatin
Description: 28-day cycles
Study NCT04542824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epcoritamab (maintenance)
Description: 28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
Study NCT04542824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab and lenalidomide
Description: 28-day cycles.
Study NCT03304054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
Study NCT03304054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: tablets matching amifampridine phosphate, 3 to 4 times a day
Study NCT02072135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Study NCT02172495 — intervention group
Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Tiotropium bromide 18 micrograms
Study NCT03216304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg safinamide
Description: Safinamide will be administered as follows:~* Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~* Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~* Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water.
Study NCT03216304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin calcium period 1
Description: Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)
Study NCT03216304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin calcium period 2
Description: - Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
Study NCT04636151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary intervention
Description: Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
Study NCT03661983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
Study NCT01800864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: obesity
Study NCT01953055 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Study NCT03716882 — intervention group
Intervention type: DEVICE
Intervention: Song Meter (SM)4
Description: Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
Study NCT03735433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 162mg aspirin dose
Description: 2 pills of 81mg aspirin
Study NCT04226378 — intervention group
Intervention type: DEVICE
Intervention: Omnipod
Description: Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.
Study NCT04226378 — intervention group
Intervention type: OTHER
Intervention: MDI
Description: Continued use of MDI therapy (traditional basal/bolus insulin regimen).
Study NCT01979484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 capsule
Study NCT01979484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668 tablet
Study NCT03655197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline
Description: For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
Study NCT03655197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
Study NCT00611286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel treatment after bare metal stent implantation
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
Study NCT00611286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel treatment after bare metal stent implantation
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
Study NCT00611286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel after zotarolimus-eluting stent implantation
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
Study NCT00611286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel after paclitaxel-eluting stent implantation
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
Study NCT00611286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel after everolimus-eluting stent implantation
Description: extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
Study NCT00611286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel after zotarolimus-eluting stent implantation
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
Study NCT00611286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel after paclitaxel-eluting stent implantation
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.